CA-C3.AI/NCS
17.6.2021 06:02:07 CEST | Business Wire | Press release
C3 AI (NYSE:AI), the Enterprise AI application software company, and NCS, a leading technology services provider and member of the Singtel Group, today announced a strategic partnership focused on delivering enterprise AI solutions to clients in Southeast Asia (SEA) and Australia/New Zealand (ANZ) across multiple industries, including telecommunications, government, financial services, transportation, and more.
This agreement represents C3 AI’s first strategic partnership with a telecommunications group. NCS will leverage its deep domain experience and technology expertise in serving governments and businesses in SEA and ANZ, investing up to S$10 million to develop and deploy enterprise AI applications created on the C3 AI® Suite. C3 AI’s solutions will also be deployed across Singtel, Optus, and other affiliated telecommunications networks to bring the advantages of enterprise AI to their operations and clients.
As the leader in enterprise AI applications, C3 AI’s offerings include the C3 AI Suite, a powerful end-to-end enterprise AI platform; C3 AI Ex Machina, a no-code solution that anyone can use to generate actionable enterprise AI insights; C3 AI CRM, the first enterprise AI-powered CRM solution custom-built for industries; and a comprehensive inventory of pre-built enterprise AI applications. These applications cover a broad range of use cases, such as C3 AI Energy Management for optimizing energy consumption and carbon emissions, C3 AI Predictive Maintenance to reduce unplanned machine downtime, and C3 AI Fraud Detection for financial transactions.
“Our partnership with C3 AI reaffirms NCS’ commitment to build a strong digital partner ecosystem that provides our clients access to world-leading technologies and enterprise solutions,” said NCS CEO Ng Kuo Pin. “We believe that the wave of enterprise-grade AI solutions has arrived and are excited to work with our clients to build the next generation of digital applications with enterprise AI embedded. We look forward to playing our part to unleash the transformative power of enterprise AI across governments and enterprises in Asia-Pacific.”
In its 2021 Global CIO Agenda survey, Gartner found that SEA and ANZ were among the fastest-growing regions in the world to apply digitalization to optimize enterprise processes1 . In addition, CIOs in these regions identified Artificial Intelligence/Machine Learning as a game-changing technology2 . To capitalize on this trend, C3 AI and NCS will establish a Center of Excellence together to jointly explore new solutions that will accelerate the adoption of enterprise AI and develop custom-built offerings tailored to the business requirements of the Asia-Pacific market.
“Our Center of Excellence will bring together experts from C3 AI and NCS to carefully study and respond to the specific needs of organizations and industries in Southeast Asia, Australia, and New Zealand,” said General Manager, Industries and Alliances at C3 AI Gene Reznik. “This will allow us to better serve customers in SEA and ANZ and provide them with the enterprise AI solutions they require to achieve their digital transformation objectives.”
“Singtel and NCS are clear leaders in the deployment and implementation of telecommunication and cloud solutions, and we are incredibly excited to be joining forces with such a respected and forward-looking partner,” said C3 AI Chairman and CEO Thomas M. Siebel. “NCS’ focus on digital transformation will help drive enterprise AI in Asia-Pacific, especially in the telecommunications industry, on a massive scale.”
1 Gartner, '2021 CIO Agenda: Global Perspectives on 'Seize This Opportunity for Digital Business Acceleration', Andy Rowsell-Jones, Tomas Neilsen, Jan-Martin Lowendahl, Chris Howard, Monika Sinha, March 05, 2021
2 Gartner, '2021 CIO Agenda: A Southeast Asia Perspective', Adrian Lee, February 03, 2021; Gartner, '2021 CIO Agenda: An Australia and New Zealand Perspective', Andy Rowsell-Jones, Brian Ferreira, Christopher Bell, December 15, 2021
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About NCS
NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of Applications, Infrastructure and Engineering. NCS also believes in building a strong partner eco-system with leading technology players and research institutions to support open innovation and co-creation.
For more information, please visit www.ncs.com.sg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616006026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom